Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $41

Benzinga · 05/11/2023 05:56
Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $45 to $41.